Innovassynth Technologies (India) Ltd
Innovassynth Technologies (India) Ltd Q4 FY26 Results & Presentation Highlights: Revenue, Margins & Order Book
Q4 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Innovassynth Technologies (India) Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Revenue from operations for the quarter ended 31-Mar-2026 was INR 5,083 lakhs, compared to INR 4,841 lakhs for the quarter ended 31-Mar-2025, showing a slight increase. EBITDA for Q4 FY26: ₹628 lakhs, up from ₹1,040 lakhs in Q4 FY25 (down from last year’s figure, showing a decline).
From Innovassynth Technologies (India) Ltd's Q4 FY26 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Revenue from operations for the quarter ended 31-Mar-2026 was INR 5,083 lakhs, compared to INR 4,841 lakhs for the quarter ended 31-Mar-2025, showing a slight increase.
- The year-on-year performance reflects a change considering the merger effective 1 Oct 2024; FY 25 figures represent only post-merger period from Oct 2024 to Mar 2025, so direct comparison has limitations.
- The presentation states shipment delays and one-time inventory adjustment impacted the previous quarter but these factors are transitory.
- Order book improved by approximately INR 60 crore during the quarter, indicating strong customer demand and revenue visibility.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Innovassynth Technologies (India) Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Life Sciences capacity expansion underway to double manufacturing capacity, aligned with CDMO demand growth (Page 6).
- Capacity expansion and quality audit success support medium-term growth visibility (Page 6).
- No specific capex amounts detailed in presentation.
- No new plant or greenfield project mentioned; focus is on expanding existing Life Sciences manufacturing capacity at Khopoli.
- Timelines not explicitly stated but capacity doubling implied as near-term given ongoing expansion mention and audit schedules (Page 6).
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Innovassynth Technologies (India) Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The presentation reports an open order book value of approximately INR 176 crores (Page 7).
- It highlights major orders received from USA-based companies with additional orders expected (Page 7).
- During the quarter, the order book improved by about INR 60 crore, reflecting continued customer demand and enhanced revenue visibility (Page 5).
- The company supports multiple customer molecules across development and commercialization stages, contributing to potential future manufacturing volumes and revenue growth (Page 5).
Innovassynth Technologies (India) Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹0 Cr, net loss ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Innovassynth Technologies (India) Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Chemfab Alkalis Ltd (Q4 FY26)
Chlor Alkali segment: ₹55.63 crore (down 1.21% YoY from ₹56.31 crore) . Key investor presentation takeaways from Chemfab Alkalis Ltd's Q4 FY26 investor presenta
- Sudarshan Pharma Industries Ltd (Q4 FY26)
Revenue from Operations for Q4 March 2026: ₹220.92 Cr (Page 41) . Key investor presentation takeaways from Sudarshan Pharma Industries Ltd's Q4 FY26 investor pr
- Jubilant Agri & Consumer Products Ltd (Q4 FY26)
Q4 FY26 Revenue from Operations: INR 4,852 MN, up 22% YoY from INR 3,983 MN in Q4 FY25 (Page 19) . Key investor presentation takeaways from Jubilant Agri & Cons
- Bhansali Engineering Polymers Ltd (Q4 FY26)
Q4 FY26 Revenue from Operations: ₹341.6 crores, a -1.0% year-on-year (YoY) decline (Page 8, 28). Key investor presentation takeaways from Bhansali Engineering P
Frequently Asked Questions
What were Innovassynth Technologies (India) Ltd Q4 FY26 results?
Revenue from operations for the quarter ended 31-Mar-2026 was INR 5,083 lakhs, compared to INR 4,841 lakhs for the quarter ended 31-Mar-2025, showing a slight increase. EBITDA for Q4 FY26: ₹628 lakhs, up from ₹1,040 lakhs in Q4 FY25 (down from last year’s figure, showing a decline).
What is Innovassynth Technologies (India) Ltd share price analysis?
Innovassynth Technologies (India) Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,338 Cr. Investors should review the full earnings analysis for detailed insights.
Is Innovassynth Technologies (India) Ltd planning capital expenditure?
Life Sciences capacity expansion underway to double manufacturing capacity, aligned with CDMO demand growth (Page 6).
Keep Innovassynth Technologies (India) Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.